Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: A systematic review

Hypertension

Volumn 60, Issue 2, 2012, Pages 444-450

  Bullo, Marina ^a   Tschumi, Sibylle ^a   Bucher, Barbara S ^a   Bianchetti, Mario G ^b   Simonetti, Giacomo D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Division of Pediatrics   (Switzerland)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; fetopathy; pregnancy; prenatal exposure; systematic review

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; QUINAPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANURIA; BRAIN DISEASE; CONGENITAL MALFORMATION; DIALYSIS; FETUS DEATH; FOLLOW UP; GESTATIONAL AGE; HUMAN; HYPOCALVARIA; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; KIDNEY FAILURE; LIMB DISEASE; LUNG HYPOPLASIA; MORTALITY; OLIGOHYDRAMNIOS; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PERSISTENT PATENT DUC; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; INFANT, NEWBORN; OLIGOHYDRAMNIOS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RENAL INSUFFICIENCY;

EID: 84864286982     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.196352     Document Type: Review

References (89)

1. Gubler MC, Antignac C. Renin-Angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int. 2010;77:400-406.
2. Guignard J, Burgener F, Cálame A. Persistent anuria in a neonatë: A side effect of captopril. Int J Pediatr Nephrol. 1981;2:133.
3. Duminy PC, Burger PD. Fetal abnormality associated with the use of captopril during pregnancy. S Afr Med J. 1981;60:805. (Pubitemid 12251265)
4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
5. Baethge BA, Wolf RE. Successful pregnancy with scleroderma renal disease and pulmonary hypertension in a patient using angiotensin converting enzyme inhibitors. Ann Rheum Dis. 1989;48:776-778. (Pubitemid 19225053)
6. Bald M, Holder M, Zieger M, Vochem M, Leichter HE. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy. Pediatr Nephrol. 2005;20: 1664-1665, 1666-1668.
7. Bass JK, Faix RG. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant. Am J Perinatol. 2006;23:313-317.
8. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol. 2004;70:547-549. (Pubitemid 39167071)
9. Boix E, Zapater P, Pico A, Moreno O. Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest. 2005;28: 1029-1031. (Pubitemid 43265771)
10. Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother. 2005; 39:157-161. (Pubitemid 40052394)
11. Boutroy MJ, Vert P, Hurault de Ligny B, Miton A. Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet. 1984;2:935-936. (Pubitemid 15201149)
12. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother. 2001;35:859-861. (Pubitemid 32678707)
13. Caraman PL, Miton A, Hurault de Ligny B, Kessler M, Boutroy MJ, Schweitzer M, Brocard O, Ragage JP, Netter P. [Pregnancy under captopril]. Therapie. 1984;39:59-62.
14. Celentano C, Prefumo F, di Vera E, Iannicco A, Gallo DP, Liberati M. Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker. Pediatr Nephrol. 2008;23:333-334.
15. Chisholm CA, Chescheir NC, Kennedy M. Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure. Am J Perinatol. 1997;14:511-513. (Pubitemid 27494787)
16. Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 2001;357:1620-1621.
17. Coen G, Cugini P, Gerlini G, Finistauri D, Cinotti GA. Successful treatment of long-lasting severe hypertension with captopril during a twin pregnancy. Nephron. 1985;40:498-500. (Pubitemid 15026174)
18. Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. BJOG. 2003;110:1038.
19. Cunniff C, Jones KL, Phillipson J, Benirschke K, Short S, Wujek J. Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol. 1990;162:187-189. (Pubitemid 20055447)
20. Daikha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R. Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol. 2006;21:729-732.
21. Ducret F, Pointet P, Lauvergeon B, Jacoulet C, Gagnaire J. [Pregnancy under converting enzyme inhibitor]. Presse Med. 1985;14:897.
22. Easterling TR, Carr DB, Davis C, Diederichs C, Brateng DA, Schmucker B. Low-dose, short-Acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol. 2000;96:956-961.
23. Filler G, Wong H, Condello AS, Charbonneau C, Sinclair B, Kovesi T, Hutchison J. Early dialysis in a neonate with intrauterine lisinopril exposure. Arch Dis Child Fetal Neonatal Ed. 2003;88:F154-F156. (Pubitemid 36269541)
24. Fiocchi R, Lijnen P, Fagard R, Staessen J, Amery A, Van Assche F, Spitz B, Rademaker M. Captopril during pregnancy. Lancet. 1984;2:1153. (Pubitemid 15210867)
25. Georgaki-Angelaki E, Stergiou N, Naoum E, Papassotiriou I, Anagnostakou M. Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: A case report and review of the literature. Nephrol Dial Transplant Plus. 2009;2:295-297.
26. Gersak K, Cvijic M, Cerar LK. Angiotensin II receptor blockers in pregnancy: A report of five cases. Reprod Toxicol. 2009;28:109-112.
27. Guron G, Molne J, Swerkersson S, Friberg P, Hansson S. A 14-year-old girl with renal abnormalities after brief intrauterine exposure to enalapril during late gestation. Nephrol Dial Transplant. 2006;21:522-525. (Pubitemid 43160012)
28. Hasbun HJ, Valdes RE, San Martin OA, Catalan MJ, Salinas QS, Parra CM. [Transient renal failure in a newborn due to angiotensin receptor II antagonist use during pregnancy: report of a case]. Rev Med Chil. 2008; 136:624-630.
29. Hinsberger A, Wingen AM, Hoyer PF. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 2001;357:1620.
30. Hulton SA, Thomson PD, Cooper PA, Rothberg AD. Angiotensinconverting enzyme inhibitors in pregnancy may result in neonatal renal failure. S Afr Med J. 1990;78:673-676.
31. Kaler SG, Patrinos ME, Lambert GH, Myers TF, Karlman R, Anderson CL. Hypertrichosis and congenital anomalies associated with maternal use of minoxidil. Pediatrics. 1987;79:434-436. (Pubitemid 17022906)
32. Kato K, Okuda M, Ishikawa H, Takahashi T, Hirahara F. Oligohydramnios and pulmonary hypoplasia: A case in which involvement of an angiotensin II receptor antagonist was suspected. J Obstet Gynaecol Res. 2008;34:242-246. (Pubitemid 351537738)
33. Knott PD, Thorpe SS, Lamont CA. Congenital renal dysgenesis possibly due to captopril. Lancet. 1989;1:451. (Pubitemid 19059202)
34. Kolagasi O, Sari F, Akar M, Sari R. Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy. Ann Pharmacother. 2009;43:147-149.
35. Kreft-Jais C, Plouin PF, Tchobroutsky C, Boutroy MJ. Angiotensinconverting enzyme inhibitors during pregnancy: A survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol. 1988;95: 420-422.
36. Lambot MA, Vermeylen D, Noel JC. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 2001;357:1619-1620.
37. Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensinconverting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed. 2007;92:F402-F403. (Pubitemid 47436230)
38. Lavoratti G, Seracini D, Fiorini P, Cocchi C, Materassi M, Donzelli G, Pela I. Neonatal anuria by ACE inhibitors during pregnancy. Nephron. 1997;76:235-236. (Pubitemid 27254658)
39. Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensinconverting-enzyme inhibitors in early pregnancy. Lancet. 1997;350: 1446-1447.
40. Mann R, Mackay F, Pearce G, Freemantle S, Wilton L. Losartan: A study of pharmacovigilance data on 14 522 patients. J Hum Hypertens. 1999; 13:551-557. (Pubitemid 29386845)
41. Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet. 2001; 358:241-242. (Pubitemid 32718555)
42. Mehta N, Modi N. ACE inhibitors in pregnancy. Lancet. 1989;2:96-97. (Pubitemid 19173309)
43. Millar JA, Wilson PD, Morrison N. Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report. N Z Med J. 1983;96:796-798. (Pubitemid 14224898)
44. Miura K, Sekine T, Iida A, Takahashi K, Igarashi T. Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker. Pediatr Nephrol. 2009;24:1235-1238.
45. Muller PR, James A. Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor. J Perinatol. 2002;22:582-584.
46. Munk PS, von Brandis P, Larsen AI. Reversible fetal renal failure after maternal treatment with Candesartan: A case report. Reprod Toxicol. 2010;29:381-382.
47. Nayar B, Singhal A, Aggarwal R, Malhotra N. Losartan induced fetal toxicity. Indian J Pediatr. 2003;70:923-924. (Pubitemid 38017033)
48. Neves S, Santos R, Gomes C, Correia AJ. [Fetopathy associated with exposure to angiotensin converting enzyme inhibitors]. Acta Med Port. 2010;23:697-700.
49. Payen V, Chemin A, Jonville-Bera AP, Saliba E, Cantagrel S. [Fetal toxicity of angiotensin-II receptor antagonists]. J Gynecol Obstet Biol Reprod (Paris). 2006;35:729-731. (Pubitemid 44683681)
50. Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol. 2003;23: 254-255. (Pubitemid 36656529)
51. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992;80: 429-432.
52. Plouin PF, Tchobroutsky C. [Inhibition of angiotensin converting enzyme in human pregnancy. 15 cases]. Presse Med. 1985;14:2175-2178. (Pubitemid 16195562)
53. Prasad N, Gulati S, Jain M, Tewari P. An unusual case of neonatal anuria. Indian Pediatr. 2003;40:258-260. (Pubitemid 36362636)
54. Pryde PG, Sedman AB, Nugent CE, Barr M Jr. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993;3:1575-1582.
55. Rhabbour M, Lenoir S, Bouissou F, Rolland M, Fournie A. [Fetal and neonatal effects of maternal treatment with angiotensin converting enzyme inhibitor]. Arch Pediatr. 1994;1:497-500. (Pubitemid 24164338)
56. Roger N, Popovic I, Madelenat P, Mahieu-Caputo D. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report]. Gynecol Obstet Fertil. 2007;35:556-560. (Pubitemid 46908785)
57. Rosa FW, Bosco LA, Graham CF, Milstien JB, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol. 1989;74:371-374. (Pubitemid 19213925)
58. Rothberg AD, Lorenz R. Can captopril cause fetal and neonatal renal failure? Pediatr Pharmacol (New York). 1984;4:189-192. (Pubitemid 15201528)
59. Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet. 2001;357:363. (Pubitemid 32128547)
60. Schaefer C. Angiotensin II-receptor-Antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol. 2003;67:591-594. (Pubitemid 37247675)
61. Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med. 1988;108: 215-216.
62. Scott AA, Purohit DM. Neonatal renal failure: A complication of maternal antihypertensive therapy. Am J Obstet Gynecol. 1989;160:1223-1224. (Pubitemid 19144495)
63. Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: A report of 10 cases. BJOG. 2005;112: 710-712. (Pubitemid 40852836)
64. Shrim A, Berger H, Kingdom J, Hamoudi A, Shah PS, Koren G. Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible. Can Fam Physician. 2005; 51:1335-1337. (Pubitemid 41600926)
65. Simonetti GD, Baumann T, Pachlopnik JM, von Vigier RO, Bianchetti MG. Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan. Pediatr Nephrol. 2006;21:1329-1330. (Pubitemid 44203462)
66. Sinelli MT, Cattarelli D, Cortinovis S, Maroccolo D, Chirico G. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists. Pediatr Med Chir. 2008;30:306-308.
67. Thorpe-Beeston JG, Armar NA, Dancy M, Cochrane GW, Ryan G, Rodeck CH. Pregnancy and ACE inhibitors. Br J Obstet Gynaecol. 1993;100:692-693. (Pubitemid 23209771)
68. Velazquez-Armenta EY, Han JY, Choi JS, Yang KM, Nava-Ocampo AA. Angiotensin II receptor blockers in pregnancy: A case report and systematic review of the literature. Hypertens Pregnancy. 2007;26:51-66. (Pubitemid 46649346)
69. Vendemmia M, Garcia-Meric P, Rizzotti A, Boubred F, Lacroze V, Liprandi A, Simeoni U. Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-Antagonists. J Matern Fetal Neonatal Med. 2005;18:137-140. (Pubitemid 41527067)
70. Yip SK, Leung TN, Fung HY. Exposure to angiotensin-converting enzyme inhibitors during first trimester: is it safe to fetus? Acta Obstet Gynecol Scand. 1998;77:570-571. (Pubitemid 28263831)
71. Esposito F, Galfetti M, Lava SA, Balestra B, Bianchetti MG. Fetopathy probably associated to self-medication with a blocker of the reninangiotensin system. Arch Gynecol Obstet. 2011;284:1321.
72. Hunseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, Korber F, Schmitt K, Welzing L, Muller A, Herkenrath P, Hoppe B, Gortner L, Roth B, Kattner E, Schaible T. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr. 2011;223:10-14.
73. Morgan M, De Jong-van den Berg LT, Jordan S. Drug safety in pregnancy-monitoring congenital anomalies. J Nurs Manag. 2011;19: 305-310.
74. Hurault de Ligny B, Mintz P, Ryckelynck JP, Herlicoviez M, Muller G, Levy G. [Captopril treatment of severe arterial hypertension in pregnancy]. J Gynecol Obstet Biol Reprod (Paris). 1987;16:643-648. (Pubitemid 17150228)
75. Haaland K. Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome. J Headache Pain. 2010;11:167-169.
76. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354: 2443-2451. (Pubitemid 43855047)
77. Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England. J Hum Hypertens. 2002;16:795-803. (Pubitemid 36007933)
78. Bowen ME, Ray WA, Arbogast PG, Ding H, Cooper WO. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol. 2008;198:e291-e295.
79. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol. 2011;31:540-545.
80. Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: A report of ninety-one pregnancies. J Hypertens. 2011;29:396-399.
81. Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjolie AK. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Diabetologia. 2011;54:1298-1303.
82. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343: d4891.
83. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002; 100:369-377. (Pubitemid 34874806)
84. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005; 73:123-130. (Pubitemid 40289535)
85. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol. 1995;9:382-385.
86. Sekine T, Miura K, Takahashi K, Igarashi T. Children's toxicology from bench to bed-Drug-induced renal injury (1): The toxic effects of ARB/ACEI on fetal kidney development. J Toxicol Sci. 2009;34 Suppl 2:SP245-SP250.
87. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensinconverting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451-456. (Pubitemid 24156732)
88. Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991;78:128-135.
89. Broughton Pipkin F, Turner SR, Symonds EM. Possible risk with captopril in pregnancy: some animal data. Lancet. 1980;1:1256. (Pubitemid 10105364)